NCT00287911View on ClinicalTrials.gov

Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Cervical Cancer
Interventions
DRUG

cisplatin

intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36

DRUG

topotecan hydrochloride

intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined

RADIATION

brachytherapy

Some patients may also undergo brachytherapy

RADIATION

radiation therapy

once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36

Trial Locations (1)

55455

University of Minnesota Cancer Center, Minneapolis

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER